Pintek is an industry veteran with deep and broad experience in the life science industry. He joins Luminex from Roche, where he has held several positions of increasing responsibility since 2001, most recently as vice president and general manager, Blood Screening, Roche Molecular Systems. Prior to Roche, his experience includes positions with Ventana Medical Systems and Abbott Laboratories’ Diagnostics Division. Pintek’s responsibilities at Luminex will encompass all aspects of the company’s operating functions, including sales, marketing, partner management, customer service, technical support, and instrument manufacturing. He will be based at Luminex headquarters in Austin, Texas.

Dr. Bridge-Cook has previously served as vice president, Luminex Molecular Diagnostics since Luminex’s acquisition of Tm Bioscience in March, 2007. Prior to Luminex, he served in a variety of senior positions at Tm Bioscience since 2001. In his new position, Bridge-Cook will have responsibility for all of the company’s assay and consumables development efforts, including Luminex Molecular Diagnostics, Luminex Bioscience Group, Biothreat, Animal Health, Chemistry R&D, Biology R&D External Research Program, and Emerging Technologies. He will be based at the company’s facility in Toronto.

Dr. Krunic has previously served as associate vice president, clinical and regulatory affairs, Luminex Molecular Diagnostics. Prior to that, she served in a variety of positions at Tm Bioscience since 2004. In her new role, Krunic will have responsibility for the research, development, and manufacturing of all molecular diagnostics products and strategies for the company. She will be based at the company’s facilities in Toronto.

“The board of directors and I are very pleased about these appointments and promotions,” said Patrick J. Balthrop, president and chief executive officer of Luminex. “Adding Mike to our management team brings to the company his impressive track record and history of achievement, plus his deep industry experience and knowledge. I am highly confident that Mike will make a significant impact on our business, to the benefit of all of the company’s stakeholders.

“Jeremy begins his new position after having made a major contribution heading Luminex Molecular Diagnostics over the past two years. Since the acquisition and integration, his leadership and management skill have been crucial to our success. He also led the significant expansion and investment in our fast-growing molecular diagnostics franchise,” continued Balthrop. “Nancy has been a driving force and major leadership presence within Luminex over the past two years. The company has increased our new product development effort under Nancy’s leadership, and she has guided the company successfully through the regulatory process for a number of our products across the company. She will continue to drive the company’s results in her new position as Vice President of Luminex Molecular Diagnostics.”